Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2012

Oct 11, 2012

5262_ffr_2012-10-11_35f11886-4c3c-4945-bf3e-c29f1ba5d10d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending October 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of the following increases in interests in Ordinary Shares in GlaxoSmithKline plc purchased at a price of 1457.14 pence per Share on 8 October 2012, in respect of the personal holdings of the under-mentioned persons

following the re-investment of the dividend paid to shareholders on 4 October 2012.

Ordinary Shares
Dr M M Slaoui 232.081
Mr S M Bicknell 68.107
Mr R G Connor 24.777
Mr M Dunoyer 328.383
Mr S A Hussain 736.891
Mr D S Redfern 253.960
Ms C Thomas 248.247
Mr P C Thomson 98.343
Dr P J T Vallance 223.919
Mr C Weber 250.439

The Company was advised of this information on 10 October 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

11 October 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: October 11, 2012

By: VICTORIA WHYTE


Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc